Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...

Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...

Medtronic plc MDT recently achieved the CE Mark for the MiniMed 780G system with Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) that does not require any fingersticks or over ...

It’s traditionally been particularly difficult to manage diabetes in highly active, still-developing children, but increasingly advanced glucose monitors and insulin delivery systems are aiming to ...

DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...

The 80th Scientific Sessions of the American Diabetes Association (ADA) — which are virtual this year, due to social distancing restrictions — is in full swing. Medtronic helped kick things off Friday ...

Medtronic reported Q1 2023 worldwide revenue of $8.544 billion, a 5.6% increase, with the Cardiovascular division contributing $3.3 billion, a 12% YoY growth. The company anticipates organic revenue ...

It’s notoriously difficult to manage blood sugar levels in children and teenagers with Type 1 diabetes because of their high activity levels, constantly fluctuating hormones and ongoing growth and ...

Medtronic plc MDT presented new clinical and real-world data on the MiniMed 780G system at the 83rd American Diabetes Association Scientific Sessions. In April, the FDA approved Medtronic's MiniMed ...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the ...